On January 25, 2022 Iterative Scopes, a pioneer in the development of precision-based gastrointestinal disease technologies, reported that it has entered into a collaboration with Janssen Research & Development, LLC (Janssen) in which Iterative Scopes will work with the Janssen Data Science and Immunology teams to augment Janssen’s clinical trials for inflammatory bowel disease (IBD) with the deployment of cutting-edge artificial intelligence (AI) and computer vision tools (Press release, Janssen Research & Development, JAN 25, 2022, View Source [SID1234606785]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Patient recruitment and clinical trial workflow inefficiencies are ongoing challenges for gastrointestinal clinical researchers and drug developers. Through this agreement, Iterative Scopes and Janssen will work together to integrate computational gastroenterology solutions to enhance assessment and interpretation of endoscopic video images, facilitating recruitment of eligible patients for Janssen’s IBD clinical trials. This collaboration has significant potential to addressing the bottlenecks in IBD clinical research, helping identify the right patients for each trial, reducing unnecessary screening costs, and accelerating trials.
"Our team at Iterative Scopes is thrilled to be collaborating with Janssen, to help solve some of the toughest problems facing drug development for Inflammatory Bowel Disease with artificial intelligence," said Jonathan Ng, Founder and CEO of Iterative Scopes.
Johnson & Johnson Innovation – JJDC, Inc., the strategic venture capital arm of Johnson & Johnson, participated with other investors in Iterative Scopes’ $30 million Series A financing, which closed in August 2021, as well as their $150 million Series B financing, which closed in December 2021.